As a clinicopathologically defined entity, dementia with Lewy bodies (DLB) has overlapping features of Alzheimer's disease (AD) and Parkinson's disease (PD). Analogous characteristics of DLB offer a provisional rationale for pharmacologic therapy based on remediating cholinergic and dopaminergic deficits, respectively. However, the distinct clinical manifestations and pathophysiologic substrates of DLB pose unique therapeutic opportunities and challenges. More severe cholinergic deficits in DLB relative to AD support clinical evidence that cholinergic therapy may be particularly beneficial in DLB patients. In contrast, DLB patients are generally more sensitive to the adverse effects of antipsychotic agents, warranting caution in treating visual hallucinations and other psychotic symptoms. Similarly, parkinsonian motor signs in DLB, often manifest as rigidity and bradykinesia, may be less amenable to dopaminergic therapies than in PD. Increasing recognition of DLB as a common form of dementia in the elderly underscores the need for large-scale, placebo-controlled therapeutic trials. (J Geriatr Psychiatry Neurol 2002; 15:000–000).
Get full access to this article
View all access options for this article.
References
1.
1. McKeith IG, Galasko D, Kosaka K, et al., Consensus guidelines for the clinical and pathological diagnosis of dementia with Lewy bodies (DLB): report on the Consortium on DLB International Workshop. Neurology1996; 47: 1113–1124.
2.
2. Hansen L, Salmon D, Galasko D, et al., The Lewy body variant of Alzheimer's disease: a clinical and pathological entity. Neurology1990; 40: 1–8.
3.
3. Saghal A, Galloway PH, McKeith IG, et al., A comparative study of attentional deficits in senile dementias of Alzheimer and Lewy body types. Dementia1992; 3: 350–354.
4.
4. Calderon J, Perry RJ, Erzinclioglu SW, et al., Perception, attention, and memory are disproportionately impaired in dementia with Lewy bodies compared with Alzheimer's disease. J Neurol Neurosurg Psychiatry2001; 70: 157–164.
5.
5. McKeith IG, Perry RH, Fairbairn AF, et al., Operational criteria for senile dementia of the Lewy body type (SDLT). Psychol Med1992; 22: 911–922.
6.
6. Samuel W, Henderson VE, Miller CE., Severity of dementia in Alzheimer's disease and neurofibrillary tangles in multiple brain regions. Alzheimer Dis Assoc Disord1991; 5: 1–11.
7.
7. Samuel W, Alford M, Hofstetter CR, Hansen L., Dementia with Lewy bodies versus pure Alzheimer's disease: differences in cognition, neuropathology, cholinergic dysfunction, and synapse density. J Neuropathol Exp Neurol1997; 56: 499–508.
8.
8. Stern Y, Jacobs D, Goldman J, et al., An investigation of clinical correlates of Lewy bodies in autopsy-proven Alzheimer disease. Arch Neurol2001; 58: 460–465.
9.
9. Hurtig HI, Trojanowski JQ, Galvin J, et al., Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology2000; 54: 1916–1921.
10.
10. Langlais PJ, Thal LJ, Hansen L, et al., Neurotransmitters in basal ganglia and cortex of Alzheimer's disease with and without Lewy bodies. Neurology1993; 43: 1927–1934.
11.
11. Perry EK, Irving D, Kerwin JM, et al., Cholinergic transmitter and neurotrophic activities in Lewy body dementia: similarity to Parkinson's and distinction from Alzheimer disease. Alzheimer Dis Assoc Disord1993; 7: 69–79.
12.
12. Tiraboschi P, Hansen LA, Alford M, et al., Cholinergic dysfunction in diseases with Lewy bodies. Neurology2000; 54: 407–411.
13.
13. Jellinger K, Bancher C, Fischer P., Neuropathological correlates of mental dysfunction in Parkinson's disease. In: Wolters C, Scheltens E, eds., Mental dysfunction in Parkinson's disease. Amsterdam: Vrije Univeriteit, 1993: 141–161.
14.
14. Perry E, Walker M, Grace J, Perry R., Acetylcholine in mind: a neurotransmitter correlate of consciousness?Trends Neurosci1999; 22: 273–280.
15.
15. Dringenberg HC., Alzheimer's disease: more than a ‘cholinergic disorder’–evidence that cholinergic-monoaminergic interactions contribute to EEG slowing and dementia. Behav Brain Res2000; 115: 235–249.
16.
16. Briel RC, McKeith IG, Barker WA, et al., EEG findings in dementia with Lewy bodies and Alzheimer's disease. J Neurol Neurosurg Psychiatry1999; 66: 401–403.
17.
17. Ballard C, Holmes C, McKeith I, et al., Psychiatric morbidity in dementia with Lewy bodies: a prospective clinical and neuropathological comparative study with Alzheimer's disease. Am J Psychiatry1999; 156: 1039–1045.
18.
18. Simard M, van Reekum R, Cohen T., A review of cognitive and behavioral symptoms in dementia with Lewy bodies. J Neuropsychiatry Clin Neurosci2000; 12: 425–450.
19.
19. Perry EK, Marshall E, Kerwin JM, et al., Evidence of a monoaminergic:cholinergic imbalance related to visual hallucinations in Lewy body dementia. J Neurochem1990; 55: 1454–1456.
20.
20. McShane R, Keene J, Gedling K, et al., Hallucinations, cortical Lewy body pathology, cognitive function, and neuroleptic use in dementia. In: Perry RH, McKeith IG, Perry EK, eds., Dementia with Lewy bodies: clinical, pathological, and treatment issues. New York: Cambridge University Press,1996: 85–98.
21.
21. Lobotesis K, Fenwick JD, Phipps A, et al., Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not AD. Neurology2000; 56: 643–649.
22.
22. Minoshima S, Foster NL, Sima AAF, et al., Alzheimer's disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation. Ann Neurol2001; 50: 358–365.
23.
23. Gnanalingham K, Byrne E, Thornton A, et al., Motor and cognitive function in Lewy body dementia; comparison with Alzheimer's and Parkinson's diseases. J Neurol Neurosurg Psychiatry1997; 62: 243–252.
24.
24. Kosaka K, Tsuchiya K, Yoshimura M., Lewy body disease with and without dementia: a clinicopoathological study of 35 cases. Clin Neuropathol1989; 7: 299–305.
25.
25. Walker Z, Costa DC, Ince P, et al., In-vivo demonstration of dopaminergic degeneration in dementia with Lewy bodies. Lancet1999; 354: 646–647.
26.
26. Grace JB, Walker MP, McKeith IG., A comparison of sleep profiles in patients with dementia with Lewy bodies and Alzheimer's disease. Int J Geriatr Psychiatry2000; 11: 1028–1033.
27.
27. Turner RS., Idiopathic rapid eye movement sleep behavior disorder is a harbinger of dementia with Lewy bodies. J Geriatr Psychiatry Neurol2002; 15: 195–199.
28.
28. Wennings GK, Scherfler C, Granata R, et al., Time course of symptomatic orthostatic hypotension and urinary incontinence in patients with postmortem confirmed parkinsonian syndromes: a clinicopathological study. J Neurol Neurosurg Psychiatry1999; 67: 620–623.
29.
29. Lingler JH, Kaufer DI., Cognitive and motor symptoms in dementia: focus on dementia with Lewy bodies. J Am Acad Nurse Pract 2002; in press.
30.
30. McKeith IG, Fairbairn A, Perry RH, et al, Neuroleptic sensitivity in patients with senile dementia of the Lewy body type. BMJ1992; 305: 673–678.
31.
31. Francis PT, Palmer AM, Snape M, Wilcock GK., The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry1999; 66: 137–147.
32.
32. Lawrence AD, Sahakian BJ., The cognitive psychopharmacology of Alzheimer's disease: focus on cholinergic systems. Neurochem Res1998; 23: 787–794.
33.
33. Cummings JL, Kaufer DI., Neuropsychiatric aspects of Alzheimer's disease: the cholinergic hypothesis revisited. Neurology1996; 47: 876–883.
34.
34. Cummings JL, Gorman DG, Shapira J., Physostigmine ameliorates the delusions of Alzheimer's disease. Biol Psychiatry1993; 33: 536–541.
35.
35. Kaufer DI, Cummings JL, Christine D., Effect of tacrine on behavioral symptoms in Alzheimer's disease: an open-label study. J Geriatr Psychiatry Neurol1996; 9: 1–6.
36.
36. Kaufer DI, Catt KE, Lopez OL, DeKosky ST., Dementia with Lewy bodies: response of delirium-like features to donepezil. Neurology1998; 51: 1512.
37.
37. Aarsland D, Bronnick K, Karlsen K., Donepezil for dementia with Lewy bodies: a case study. Int J Geriatr Psychiatry1999; 14: 69–72.
38.
38. Shea C, MacKnight C, Rockwood K., Donepezil for treatment of dementia with Lewy bodies: a case series of nine patients. Int Psychogeriatr1998; 3: 229–238.
39.
39. McKeith IG, Del Ser T, Spano P, et al., Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet2000; 356: 2031–2036.
40.
40. Physician's desk reference. Montvale, NJ: Medical Economics, 2001.
41.
41. Cummings JL., Cholinesterase-inhibitors: a new class of psychotropic compounds. Am J Psychiatry2000; 157: 4–15.
43. Newhouse PA, Potter A, Levin ED, et al., Nicotinic system involvement in Alzheimer's and Parkinson's diseases. Drugs Aging1997; 11: 206–228.
44.
44. Knapp MJ, Knopman DS, Solomon PR, and the Tacrine Study Group. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA1994; 271: 985–991.
45.
45. Rogers SL, Friedhoff LT, and the Donepezil Study Group, The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a multicentre, randomized, double-blind, placebocontrolled trial. Dementia1996; 7: 292–303.
46.
46. Corey-Bloom J, Anand R, Veach J, for the ENA-713 (rivistigmine tartrate) B352 Study Group., A randomized trial evaluating the efficacy and safety of ENA-713, a new cholinesterase-inhibitor in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychiatry1998; 1: 55–65.
47.
47. Raskind MA, Peskind ER, Wessel T, Yuan W, for the Galantamine USA-1 Study Group., Galantamine in AD: a six-month randomized, placebo-controlled trial with a 6-month extension. Neurology2000; 54: 2261–2268.
48.
48. Ballard CG, Grace J, McKeith IG, et al., Neuroleptic sensitivity in dementia with Lewy bodies and Alzheimer's disease. Lancet1998; 351: 1032–1033.
49.
49. Katz IR, Jeste DV, Mintzer JE, et al., Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. J Clin Psychiatry1999; 60: 107–115.
50.
50. De Duyn PP, Rabheru K, Rasmussen A, et al., A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology1999; 53: 946–955.
51.
51. Allen RL, Walker Z, D'Ath PJ, et al., Risperidone for psychotic and behavioural symptoms in Lewy body dementia. Lancet1995; 346: 185.
52.
52. Street JS, Clark WS, Gannon KS, et al., Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. Am J Psychiatry2000; 57: 968–976.
53.
53. Walker Z, Grace J, Overshot R, et al., Olanzapine in dementia with Lewy bodies: a clinical study. Int J Geriatr Psychiatry1999; 14: 459–466.
54.
54. McManus DQ, Arvantis LA, Kowalcyk BB, et al., Quetiapine, a novel antipsychotic: experience in elderly patients with psychotic disorders. J Clin Psychiatry1999; 60: 292–298.
55.
55. Campbell S, Stephens S, Ballard C., Dementia with Lewy bodies: clinical features and treatment. Drugs Aging2001; 18: 397–407.
56.
56. Louis ED, Klatka LA, Liu Y, et al., Comparison of extrapyramidal features in 31 pathologically confirmed cases of diffuse Lewy body disease and 34 pathologically confirmed cases of Parkinson's disease. Neurology1997; 48: 376–380.
57.
57. Ringman JM, Simmons JH., Treatment of REM sleep behavior disorder with donepezil: a report of three cases. Neurology2000; 55: 870–871.
58.
58. Senard JM, Brefel-Courbon C, Rascol O, Montastruc JL., Orthostatic hypotension in patients with Parkinson's disease. Drugs Aging2001; 18: 495–505.
